Duke Choudhury

Radiopharmaceuticals Market size is anticipated to witness growth at a CAGR of 9.8% between 2024 and 2032. To know more, visit:- https://lnkd.in/dz9tfWNx Key players are:-   General Electric Manufacturing Company (GEMAC) IRE - Institute for radioelements ISO-TEX DIAGNOSTICS, INC. Jubilant Pharmova Limited Lantheus Novartis #Radiopharmaceuticals #NuclearMedicine #MedicalImaging #PETScan #SPECT #RadioactiveIsotopes #TargetedTherapy #CancerTreatment #DiagnosticImaging #Theranostics #Radioimmunotherapy #Radiology #PatientCare #HealthcareInnovation #Oncology #RadiationTherapy #Pharmaceuticals #MedicalResearch #HealthTechnology #ClinicalTrials

2

💡 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐋𝐢𝐯𝐞𝐬: 𝐓𝐡𝐞 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 💡 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/gW99jZ7u Diabetes management is critical to improving the quality of life for millions worldwide. With innovative solutions and continuous advancements, the diabetes management market is leading the way in effective disease management and prevention. Here’s why the diabetes management market is vital: 1️⃣ Innovative Technologies: From continuous glucose monitors (CGMs) to insulin pumps and smart insulin pens, technology is revolutionizing how diabetes is managed, providing real-time data and enhancing treatment precision. 2️⃣ Personalized Care: Advances in diabetes management enable personalized treatment plans tailored to individual needs, optimizing glycemic control and reducing the risk of complications. 3️⃣ Digital Health Integration: Mobile apps and telemedicine platforms are making diabetes management more accessible and convenient, allowing patients to track their health, consult with healthcare providers, and adjust treatments from anywhere. 4️⃣ Preventive Solutions: Emphasis on early detection and lifestyle interventions, such as diet and exercise programs, help prevent the onset of diabetes and manage prediabetes effectively. 5️⃣ Educational Resources: Increased availability of educational tools and support programs empower patients to understand and manage their condition better, fostering adherence to treatment plans and healthy living. #Company Ascensia Diabetes Care Abbott Medtronic Roche Dexcom Insulet Corporation Tandem Diabetes Care LifeScan AgaMatrix ARKRAY,Inc. BD Eli Lilly and Company #Type Monitoring Devices Diagnostic Devices Insulin Delivery Devices Other Devices #Application Hospital Clinic Home Care #DiabetesManagement #HealthTech #PatientCare #InnovativeSolutions #DigitalHealth #PersonalizedMedicine #PreventiveCare #HealthcareInnovation #GlobalHealth

2

Booth No : #B15 Chennai Trade Center, Tamil Nadu Exciting News! Join us at Pharmac South Exhibition for a groundbreaking exploration of pharmaceutical advancements. Network with industry leaders and discover the latest innovations shaping the future of healthcare. Don't miss out! #PharmacSouth #HealthcareInnovation #MedicalExpo #PharmaTech #IndustryLeaders #NetworkingEvent #FutureOfHealthcare #herbalextract #botanicalextract #herbalcreations #herbalcreationsusa

4

Growth forecast of Indian PHARMA FY25. ~~~~~~~~~~~~~~~~~~~~~~~~ IPM are set to experience 9-11 per cent revenue growth in FY25, driven by strong performances in key markets such as the United States, Europe, and emerging regions, according to a recent report by credit rating agency Icra. However, this growth represents a moderation from the 13-14 per cent year-on-year (Y-o-Y) increase recorded in FY24, which was driven by higher demand and new product launches. The domestic market is expected to see a positive turnaround, with Icra projecting revenue growth of 7-9 per cent for its sample set of companies in FY25. This is an improvement from the 6.4 per cent growth recorded in FY24. The change in the National List of Essential Medicines (NLEM) and an uneven monsoon impacted growth in the previous year. However, better sales force strategies, wider distribution in rural areas, and new product launches are expected to drive growth in FY25, despite minimal price hikes under the new NLEM. The US market is expected to remain the biggest contributor to revenue growth. This comes after FY24, where Indian pharma companies saw an 18.3 per cent rise in revenue from the US. Factors like new product launches, faster approvals, and pricing benefits due to supply chain disruptions have fuelled this growth. However, Icra cautions that the sustainability of these factors in FY25 remains to be seen. Source: https://lnkd.in/g49TUv8M

2